FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Hosted on MSN11d
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Summerlin offers homes ready for immediate occupancy
The Summerlin master-planned community offers more than 75 unique floor plans in 15 neighborhoods throughout eight distinct ...
pv magazine International8d
Five Years of Innovation—-Trinasolar Leads the 210mm Module Revolution
At the recent 210mm Five-Year Ecological Innovation Conference, Dr. Zhang Yingbin, Head of Strategy, Product, and Marketing at Trinasolar, took the stage to highlight the transformative impact of the ...
Yahoo Finance7d
The RMR Group Inc. (RMR)
NEWTON, Mass., February 05, 2025--The RMR Group Inc. (Nasdaq: RMR) today announced its financial results for the fiscal quarter ended December 31, 2024, which can be found at the Quarterly Results ...
techworm.net26d
10 Best Dark Themes for Windows 10 in 2025
Even the icons used in OBLIQ Dark there are super minimalistic and they belong to the Vertex icon pack. The icons in File Explorers ... 8 different style split across two designs – round and square.
Business Wire12d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...